ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
April 04, 2024 07:00 ET
|
ADC Therapeutics SA
Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all...
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
April 03, 2024 07:00 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024,...
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
April 02, 2024 17:46 ET
|
FibroGen, Inc.
FG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246 at ≥ 1.2 mg/kg in heavily pre-treated, biomarker unselected patients: Median...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
April 01, 2024 16:05 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the “Company”) (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of...
Global Single-use Assemblies Market Projected to Surge to USD 39.97 Billion by 2030
March 29, 2024 05:35 ET
|
Research and Markets
Dublin, March 29, 2024 (GLOBE NEWSWIRE) -- The "Global Single-use Assemblies Market Size, Share & Trends Analysis Report by Product (Bag Assemblies, Filtration Assemblies), Application...
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
March 13, 2024 07:00 ET
|
ADC Therapeutics SA
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings Focused...
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
March 06, 2024 07:15 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the...
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
March 06, 2024 07:00 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024, at 8:30...
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 27, 2024 07:00 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the TD Cowen...
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
February 21, 2024 08:00 ET
|
Vaccinex, Inc.
Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against...